IP Library › Granted Patent US 10,689,427
Granted Patent B2
US 10,689,427 · App. 16/157,261 · Granted Jun 23, 2020

Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels

Inventors: Jasbir Seehra (Lexington, MA); Robert Scott Pearsall (North Reading, MA); Ravindra Kumar (Acton, MA)
Assignee: ACCELERON PHARMA INC.
C07K14/495A61K31/00A61K31/454A61K31/7068A61K38/1709A61K38/179A61K38/1796A61K38/1816A61K38/193A61K39/39533A61K45/06C07K14/475C07K14/505C07K14/71A61K2300/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,689,427
App. No.
16/157,261
Granted
Jun 23, 2020
Kind
B2
Abstract

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Claims (17)

1. A method for treating a hypoproliferative anemia in a subject in need thereof; comprising administering to the subject a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1, wherein the polypeptide comprises an acidic amino acid at the position corresponding to position 79 of SEQ ID NO: 1, wherein the polypeptide binds to GDF11 and/or myostatin; and wherein the hypoproliferative anemia is an anemia associated with a hypometabolic state.

2. The method of claim 1 , wherein the hypometabolic state is selected from the group consisting of: Addison's disease, hypothyroidism, hyperparathyroidism, male castration, and reduced dietary intake of protein.

3. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1.

4. The method of claim 1 , wherein the acidic amino acid is glutamic acid.

5. The method of claim 1 , wherein the acidic amino acid is aspartic acid.

6. The method of claim 1 , wherein the polypeptide binds to GDF11.

7. The method of claim 1 , wherein the polypeptide binds to myostatin.

8. The method of claim 1 , wherein the polypeptide further comprises a constant region of an immunoglobulin.

9. The method of claim 8 , wherein the constant region is derived from an IgG heavy chain.

10. The method of claim 8 , wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 28.

11. The method of claim 8 , wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 28.

12. The method of claim 8 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 28.

13. A method for treating an acute post-hemorrhagic anemia in a subject in need thereof; comprising administering to the subject a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1, wherein the polypeptide comprises an acidic amino acid at the position corresponding to position 79 of SEQ ID NO: 1, wherein the polypeptide binds to GDF11 and/or myostatin.

14. The method of claim 13 , wherein the acute post-hemorrhagic anemia results from trauma or postpartum hemorrhage.

15. A method for treating a hypoproliferative anemia in a subject in need thereof; comprising administering to the subject a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1, wherein the polypeptide comprises an acidic amino acid at the position corresponding to position 79 of SEQ ID NO: 1, wherein the polypeptide binds to GDF11 and/or myostatin; and wherein the hypoproliferative anemia is a chronic iron-deficiency anemia.

16. The method of claim 15 , wherein the disordered red blood cell maturation is associated with the formation of undersized (microcytic), oversized (macrocytic), misshapen, or abnormally colored (hypochromic) red blood cells.

17. A method for treating an anemia associated with disordered red blood cell maturation in a subject in need thereof; comprising administering to the subject a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1, wherein the polypeptide comprises an acidic amino acid at the position corresponding to position 79 of SEQ ID NO: 1, wherein the polypeptide binds to GDF11 and/or myostatin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2019
From: SEEHRA, JASBIR; PEARSALL, ROBERT SCOTT; KUMAR, RAVINDRA
To: ACCELERON PHARMA INC.
Reel/Frame 049329/0132 →
Continuity (10)
Continuation 15790400 · Oct 23, 2017
Continuation 15221341 · Jul 27, 2016
Continuation 14201192 · Mar 7, 2014
Continuation 13542269 · Jul 5, 2012
Continuation 12856420 · Aug 13, 2010
Continuation In Part 12583177 · Aug 13, 2009
Continuation In Part PCTUS2009004659 · Aug 13, 2009
Provisional Application 61305901 · Feb 18, 2010
Provisional Application 61189094 · Aug 14, 2008
Related Publication 20190263876A1 · Aug 29, 2019
Cited By (2)
US 12,186,370 US 12,421,296